Abcuro is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells.

Abcuro is committed to developing a new class of immune modulatory bio-therapeutics for treating autoimmunity and cancer.

Abcuro’s foundational IP was developed in 2016 by Dr. Steven A Greenberg. The company is headquartered in Newton, Massachusetts.


Abcuro is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.


Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.


Abcuro is backed by RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Mass General Brigham Ventures, Sanofi Ventures, Pontifax Venture Capital, Hongsen Investment Group, New Leaf Ventures, Tekla Capital Management, and others. The company raised $155M in an oversubscribed Series B round on Aug 17, 2023. This brings Abcuro's total funding to $214.8M to date.



  • Year founded: 2016
  • Funding Info: $214.8M over 5 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Newton
  • State: Massachusetts
  • Country: United States
Related businesses